GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Exam Corner/Refined Lactulose Hydrogen Breath Test (LHBT)
19

Refined Lactulose Hydrogen Breath Test (LHBT)

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated June 1, 2025

The refined Lactulose Hydrogen Breath Test (LHBT) is a noninvasive and efficient diagnostic tool used to detect Small Intestinal Bacterial Overgrowth (SIBO) and classify Irritable Bowel Syndrome (IBS) patients based on their hydrogen production levels. This study aimed to enhance the accuracy of LHBT by optimizing its diagnostic parameters and improving patient differentiation.

Key improvements included defining the optimal hydrogen cutoff level at 20 ppm, which balanced sensitivity (77%) and specificity (88%) for detecting SIBO. The orocecal transit time (OCTT) was verified using scintigraphy, establishing an 80-minute diagnostic window. This refinement minimized false positives caused by rapid intestinal transit and improved precision compared to previous 90-minute guidelines.

The study analyzed 206 participants, including healthy controls, SIBO-predisposed individuals, and IBS patients. IBS patients were subdivided into high-hydrogen IBS (above 20 ppm) and low-hydrogen IBS (below 20 ppm). High-hydrogen IBS patients showed bacterial overgrowth patterns similar to confirmed SIBO cases, particularly in diarrhea-predominant IBS (IBS-D), which had significantly higher hydrogen levels compared to constipation-predominant IBS (IBS-C).

The effectiveness of antibiotic therapy was validated, as high-hydrogen IBS patients experienced reduced hydrogen levels and symptom relief after treatment, confirming SIBO’s role in their symptoms. Statistical analyses, including ROC curve and AUC evaluations, demonstrated the reliability of the 20 ppm cutoff.

This refined LHBT method provides a robust framework for diagnosing SIBO and stratifying IBS patients. It offers clinicians a precise tool to identify SIBO-related IBS cases and guide targeted treatment strategies, such as antibiotics, for symptom management.

Related Q&A

20

REBYOTA®, CDI and IBS

REBYOTA® (fecal microbiota, live-jslm) is an FDA-approved microbiota-based therapy designed to prevent recurrent Clostridioides difficile infection (rCDI). The PUNCH CD3-OLS trial explored its safety and efficacy in patients...

21

pharmacomicrobiomics - Cancer Immunotherapy, Transplant and IBD

Pharmacomicrobiomics is a burgeoning field that investigates how variations in the gut microbiome influence individual drug responses. In the context of cancer immunotherapy, organ transplantation, and inflammatory bowel...

22

NF-kB and Fibrosis

NF-κB and Fibrosis: A Detailed Overview Nuclear Factor-kappa B (NF-κB) is a transcription factor that plays a pivotal role in inflammation, immunity, cell survival, and apoptosis. Dysregulation of...

23

Toll-Like Receptors (TLRs)

Toll-Like Receptors (TLRs): Simplified Overview Toll-like receptors (TLRs) are proteins that play a crucial role in the innate immune system, which is the body’s first line of defense...

24

PAMPS in Liver disease

Pathogen-associated molecular patterns (PAMPs) are conserved microbial molecules derived from bacteria, viruses, fungi, and parasites that play a critical role in the development and progression of liver diseases....

25

Colorectal Cancer and PUFA

Colorectal cancer (CRC) is a significant global health issue, with diet and lifestyle being critical factors in its development and prevention. Among dietary components, polyunsaturated fatty acids (PUFAs)...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer